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in eukaryotic cells, the initiation of DnA rep-
lication is regulated by the formation of the 
pre-replication complex (pre-RC) on replica-
tion origins. Pre-RC is formed by the sequential 
loading of the origin recognition complex 
(ORC), licensing factors Cdt1 and Cdc6 and, 
eventually, the mini-chromosome mainte-
nance (MCM) complex, the presumptive DnA 
replication helicase.1 Replication factor Cdt1 
accumulates in the nucleus in G1 phase and 
plays an essential role in pre-RC assembly 
by directly recruiting the MCM complex. in 
early s phase, when replication is initiated, 
two independent pathways contribute to 
Cdt1 downregulation. First, Cdt1 is degraded 
by the ubiquitin-proteasome pathway in a 
replication-dependent manner.2 second, in 
metazoan, Cdt1 interacts with Geminin, a pro-
tein that accumulates in s phase and inhibits 
the loading of the MCM complex in a dose-
dependent manner.3 This tight regulation of 
Cdt1 ensures that MCM complex is loaded 
only during the G1 phase and that replication 
occurs only once per cell cycle.
investigations are currently ongoing to 
decipher the molecular mechanisms by which 
mammalian Cdt1 loads the MCM complex. On 
the one side, Cdt1 physically interacts with 
several subunits of the MCM complex.4,5 On 
the other side, Cdt1 interacts with enzymes 
involved in the regulation of the chromatin 
structure, such as, in human cells, histone 
acetylase HBO1 and deacetylase HDAC11.6,7 
Recent genome-wide analyses also indicate 
that replication origins are located in a specific 
chromatin environment in mammalian cells.8 
yet, whether Cdt1 is involved in chromatin 
remodeling at origins and whether chromatin 
remodeling favors MCM loading needs to be 
addressed. 
 in a previous issue of Cell Cycle, P.G. wong 
and colleagues addressed this important 
issue.9 Using a powerful in vivo engineered 
system to monitor targeted chromatin remod-
eling events, wong et al. assessed the ability 
of Cdt1 to induce chromatin remodeling. in 
brief, a reporter composed of a repeat of 
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Lac-operator (LacO) was used to monitor the 
impact of Laci-fusion proteins on the sur-
rounding chromatin structure. The fusion pro-
tein Laci-Cdt1 is tethered on LacO and induces 
a strong decondensation of the chromatin, 
while a fusion between Laci and Cdc6 does 
not. importantly, overexpression of Geminin 
suppresses Laci-Cdt1-induced chromatin 
decondensation, providing strong evidence 
that the reporter system can recapitulate 
Cdt1 function and its regulation by Geminin. 
in addition, when using cell cycle markers, 
wong  et al. observed that Laci-Cdt1 foci are 
decondensed only when cells are in G1 phase, 
at the time of pre-RC assembly and condensed 
in all other phases of the cycle. These observa-
tions are the first demonstration that Cdt1 
induces chromatin remodeling and enhances 
DnA accessibility when tethered to the chro-
matin in G1. A mutant approach identifies a 
central domain of human Cdt1 encompassing 
residues 201-355 as the region necessary for 
chromatin remodeling. This domain overlaps 
with the region previously described as essen-
tial for cell proliferation, further supporting 
the idea that chromatin remodelling activity is 
important for Cdt1 function.4
How is Cdt1 controlling chromatin decon-
densation in G1? Using their reporter system, 
wong et al. demonstrated that histone acety-
lase HBO1 and deacetylase HDAC11 regulate 
Cdt1- and cell cycle-dependent chromatin 
remodeling. in their assay, overexpression of 
HDAC11 or expression of an HAT-deficient 
HBO1 suppresses Laci-Cdt1 ability to decon-
dense the chromatin. Thus, HBO1 functions as 
a coactivator of Cdt1, and HDAC11 functions 
as a repressor of Cdt1 activity. Consistent with 
this conclusion, recent reports demonstrated 
that HBO1 is recruited onto origins during 
the G1 phase and that HBO1 acetylase activity 
is essential to load the MCM complex.6,10 in 
contrast, HDAC11 interacts with Cdt1 specifi-
cally during s phase when pre-RC formation is 
prevented.7 Thus, wong et al. proposed an 
appealing molecular model where the cell 
cycle regulation of the chromatin structure 
at replication origins relies on the sequen-
tial  interaction between Cdt1 and HBO1 dur-
ing G1 phase and Cdt1 and HDAC11 during 
s  phase. nevertheless, there is still no evi-
dence that HBO1 and HDAC11 binding are 
mutually exclusive on Cdt1. indeed, whether 
both proteins competitively interact with the 
same region on Cdt1 or whether post-traduc-
tional modifications, such as Cyclin-dependent 
kinase phosphorylation, regulates their inter-
action or enzymatic activities during the cycle 
should be investigated.
is chromatin decondensation required 
for MCM loading? wong et al. observed that 
Laci-Cdt1 decondensed foci are bound by the 
MCM complex. On the contrary, in a few cases, 
Laci-Cdt1, even if present on LacO, could not 
decondense the chromatin structure, and MCM 
complex binding could not be detected by 
immunofluorescence. These important obser-
vations indicate that Cdt1 tethering alone is 
not sufficient to target the MCM complex, 
and that chromatin decondensation is neces-
sary to load the MCM complex. nevertheless, 
decondensation induced by fusion proteins 
such as Laci-vP16, Laci-p53 or Laci-e2F is not 
sufficient to recruit the MCM complex. Thus, 
Cdt1 is somehow necessary to attract the MCM 
complex onto the chromatin. whether it is 
Cdt1 itself or a Cdt1-associated factor remains 
elusive. indeed, Cdt1 directly interacts with the 
MCM complex in cells,4,5 while HBO1 interacts 
with Cdt1 and the MCM complex and may 
physically bridge them together.6 
Lastly, using their reporter system, wong 
et al. investigated the role of Cdt1 repres-
sor Geminin. As already mentioned, overex-
pression of Geminin suppresses Laci-Cdt1 
remodelling activity, providing a possible 
mechanistic support for Geminin inhibitory 
function. wong  et al. made two additional 
observations to reinforce this conclusion. 
Firstly, Geminin stregthens the physical interac-
tion between Cdt1 and co-repressor HDAC11. 
secondly, the Cdt1 region necessary for chro-
matin remodeling (residues 201–355) is also 
a part of the Geminin interaction domain.4 
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Therefore, in s  phase, Geminin blocks Cdt1-
dependent chromatin decondensation by 
masking residues important for this activity.
P.G. wong and colleagues established that 
Cdt1-dependent chromatin remodeling is 
essential prior to MCM complex loading in G1 
and that Geminin prevents Cdt1-dependent 
chromatin remodeling. Future work should 
assess the role of chromatin in regulating 
MCM loading. is DnA accessibility sufficient 
for efficient MCM loading? Alternatively, are 
there specific histone marks deposited by Cdt1 
coactivators and read by specific DnA replica-
tion factors? Finally, one should investigate 
whether the interaction between MCM and 
Cdt1 is controlled by post-translational events 
triggered by Cdt1 and its co-activators. The 
elegant cell culture system described by wong 
et al. should make these investigations easier. 
it also opens new avenues for researchers to 
design genome-wide screens aimed at the 
characterization of new regulators of pre-RC 
assembly.
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Cutaneous T-cell lymphoma (CTCL) is a rare 
type of non-Hodgkin lymphoma, which is a 
cancer of lymphatic system. CTCLs are charac-
terized by the uncontrolled growth of a type 
of white blood cells called T cells. Mycosis 
fungoides (MF) and sezary syndrome (ss) are 
two common CTCLs, and both patients suffer 
with skin defects. The 5-year survival rate of 
the patients diagnosed as CTCL in early stage 
is 97%, but it was decreased to 41% in patients 
with an advanced stage of the disease.1 
Different therapies, including chemotherapy 
and ionizing radiation, were applied but with 
limited success. Target-based approaches are 
urgently needed to develop novel diagnostic 
markers and therapeutic methods. One recent 
study by nihal et al. showed that Polo-like 
kinase (Plk1), a critical regulator in many cell 
cycle-related events, is overexperessed in the 
CTCL patients. Moreover, genetic knowdown 
of Plk1 by RnAi or enzymatic inhibition of Plk1 
by a small molecule inhibitor was shown to 
result in a significant inhibition of CTCL cell 
growth.2 This groundbreaking work suggested 
that overexpression of Plk1 might be a novel 
prognostic marker and that targeting Plk1 in 
CTCLs could be a promising therapeutic strat-
egy for CTCL treatment.2
Plk1 is a serine-threonine kinase, which has 
been characterized as a critical player in many 
cell cycle-related events, such as mitotic entry, 
bipolar spindle formation, sister chromatid 
segregation and cytokinesis.3 Accumulating 
data suggest that Plk1 acts as a coordinator 
to couple cell cycle progression and the DnA 
damage checkpoint pathways, specifically, by 
silencing  the checkpoint signal to promote 
cell proliferation.3 interestingly, Plk1 overex-
pression is found not only in various carci-
nomas, such as melanomas, ovarian cancer, 
non-small cell lung cancer, head and neck car-
cinoma and gastric cancer, but also in several 
neoplasms including lymphomas/leukemias.4 
it has been proposed that Plk1 is an attrac-
tive target for treatments of carcinomas and 
neoplasms, but further validation is urgently 
needed.
in the study reported by nihal et al., the 
expression of Plk1 both in protein and tran-
script levels were shown to increase in mul-
tiple CTCL cell lines, including HH, Hut78, 
MyLa, seAX and sZ4. This finding is consis-
tent with their immunohistochemical study 
showing that Plk1 expression was elevated 
in the advanced lesions from patients with 
CTCL.5 More significantly, the authors evalu-
ated the effects of Plk1 inhibition on cell viabil-
ity, growth and proliferation of CTCL cells. 
They found that Plk1 inhibition via RnAi or 
Gw843682X (a small molecule Plk1 inhibitor) 
treatment dramatically reduces the cell viabil-
ity, slows down the growth and decreases 
the proliferation activity of these cell lines. 
Mechanistically, the authors demonstrated 
that Plk1 inhibition in these cell lines results 
in a G2/M cell cycle arrest, which is consistent 
with the critical function of Plk1 for mitotic 
entry. Further, they found that the levels of 
Cyclin B1 and Cdc25C proteins are increased 
upon Plk1 inhibition, supporting the G2/M 
arrest phenotype. Mitotic abnormalities were 
also observed in Plk1-inhibited CTCL cells, 
namely, the formation of monopolar spindle. 
These phenotypes provide a solid mechanism 
to support the notion that reduced cell viabil-
ity, slow growth and decreased proliferation 
of CTCL cells are due to the inhibition of Plk1. 
Being cautious enough, the authors followed 
the fate of G2/M arrested cells by Plk1 inhibi-
tion, and they found that these cells under-
went apoptosis by FACs analysis and cleaved 
PARP immunoblotting analysis.
in summary, Plk1 was predicted to be a 
novel prognostic marker for CTCL, and Plk1 
inhibition might be a good strategy to treat 
CTCL.
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Figure 1. various genetic alterations in the p53 pathway can result in attenuation of transcriptional responses to DnA damage.
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Three decades of intensive research on the 
p53 tumor suppressor have simplified some 
fundamental issues regarding human cancer. 
Cancer is a general term referring to many 
distinct neoplastic diseases, yet, remarkably, 
it has become clear that most if not all tumors 
harbor disturbances in the p53 pathway.1 The 
price of discovering this unifying defect is the 
ever more complex picture we are acquiring 
on the biological processes that p53 has a 
hand in.2 some of these activities are likely to 
have a direct impact on protecting us from 
tumorigenesis, such as p53’s role in induc-
ing senescence, apoptosis or cell cycle arrest, 
whereas the potential impact on cancer of 
other more recently discovered biological pro-
cesses governed by p53, such as autophagy, 
immune response and metabolism may be 
more difficult to pinpoint. 
Given the importance of p53 in protecting 
us from cancer, it comes as no surprise that a 
germline mutation in TP53 or the genes con-
trolling expression or activity of the protein 
increases an individual’s risk of cancer if the 
mutation causes loss of function. Copy num-
ber alteration in major genes of the pathway, 
or intragenic deletions and nonsense muta-
tions are predictably detrimental, but other 
variants or mutations that could debilitate 
the p53 pathway, such as snPs in promoter 
regions of TP53 or its regulators (Fig. 1), may 
be more cumbersome to find or more difficult 
to distinguish from innocuous sequence varia-
tion. On the researcher’s wish list is surely a 
crystal ball that would simply tell us straight-
away whether an individual has a properly 
functioning p53 pathway, without resorting 
to extensive DnA sequencing or, in the case of 
newly identified mutations, conducting exper-
iments to assess phenotypic consequences 
of the sequence variant. A simple measure 
of p53 pathway functional integrity despite 
complexities of its regulatory network and the 
numerous activities that p53 performs would 
have potential as a biomarker of risk, and as a 
research tool for geneticists. 
since p53 is a transcription factor, its abil-
ity to transactivate or repress the p53 down-
stream genes is a logical starting point for 
developing an assay of p53 pathway sta-
tus overall, yet here too, the complexity is 
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The treatment of approximately 70% of all 
breast cancers is influenced by the depen-
dence of such tumors on estrogen recep-
tor (eR) activity.1-3 eR-dependent cancers 
are currently treated by modulation of 
estrogen levels (e.g., letrazole), the use of 
selective estrogen receptor modulators 
(e.g., tamoxifen) or estrogen receptor antago-
nists (e.g.,  fulvestrant). These therapies are 
generally effective for eR-positive breast can-
cers, but recurrence and ultimately therapeu-
tic failure are major clinical problems.1,4 The 
recent study by Lehn and colleagues demon-
strates that disruption of the retinoblastoma 
tumor suppressor (RB) pathway is associated 
with resistance to tamoxifen.5
The retinoblastoma tumor suppressor 
is a critical negative regulator of cell cycle 
that is functionally inactivated in a signifi-
cant fraction of human cancers.6,7 inactivation 
of RB  can occur via multiple independent 
events in breast cancer; however, such inac-
tivation is reliant on two simple principles. 
First, RB  growth-suppressive functions are 
attenuated by phosphorylation. Consonantly, 
RB  phosphorylation is requisite for efficient 
cellular proliferation in all studied tissues. in 
tumors, aberrant phosphorylation of RB is 
a consequence of deregulated CDK/cyclin 
activity and is frequently driven by CDK4/
cyclin  D1. Cyclin  D1 amplifications occur in 
approximately 15% of breast cancers, and 
overexpression of cyclin D1 is a particularly 
common feature of eR-positive disease.8 
second, RB function has been observed to be 
compromised in a subset via mutation, genetic 
loss, epigenetic silencing and perhaps disrup-
tion of downstream signaling.6 in such con-
texts, failure to phosphorylate the RB protein is 
typically observed and is attributed in part to 
the fact that common, tumor-associated point 
mutations of RB compromise its ability to 
serve as a CDK/cyclin substrate.9 Additionally, 
tumors with RB loss typically express very high 
levels of the CDK4/6 inhibitor p16ink4a.10,11   
A recent study published in Cell Cycle 
exploited RB phosphorylation status as a 
means to define tumors that have lost normal 
RB-pathway control. By focusing on tumors 
that are phospho-RB-negative yet retain high 
proliferation rate, the study defined a spe-
cific subtype of tumor that either lacks RB 
or exhibits some other dysregulation in the 
RB pathway that enables proliferation in the 
absence of RB phosphorylation. The ability 
of this approach to define RB-pathway sta-
tus is complementary to total RB staining 
or other surrogates of RB-pathway status, 
such as p16ink4a levels.10 in each context, 
the proliferation marker (Ki67) is used for dis-
criminating indolent tumors from those with 
inactivation.5,10
Consistent with prior studies, the method 
used here by Leah and colleagues finds that 
disruption of the RB pathway is predomi-
nant amongst eR-negative breast cancers. 
specifically, loss of RB function is associated 
with ~40% of eR-negative cancer as opposed 
to ~5% of eR-positive cases. in eR-positive 
disease, the loss of RB-pathway function was 
associated with a lack of clinical benefit with 
tamoxifen. Although the overall size of the 
patient population was small, the results were 
significant in multivariate analyses, thus rein-
forcing the concept that RB loss portends 
daunting. The repertoire of p53-modulated 
genes is large, so which of the several hundred 
downstream genes is the best monitor? Or 
should we assess the whole transcriptome 
with high throughput technology?  P53 influ-
ence on the transcriptome is affected by the 
tissue and cell type,3 so what cell type should 
we use to identify individuals at higher risk of 
cancer because of genetic alterations in p53 
pathway genes?
in a recent issue of Cell Cycle, Kabacik and 
colleagues addressed these challenges.4 They 
used a multiplex RT-PCR-based procedure to 
assess the ability of ex vivo ionizing radiation 
(iR) to induce expression of three known p53 
target genes, CDKN1A (p21), BBC3 (PUMA) and 
SESN2, in blood samples, and showed that the 
transcriptional response to iR, particularly of 
PUMA, is severely compromised in blood sam-
ples from mice lacking both copies of either 
Atm, Chek2 or Trp53 itself. Haploinsufficiency 
results in an intermediate induction of PUMA 
that is still considerably lower than in samples 
from wild-type mice. The authors propose that 
the blood test can be used as a simple assay 
to identify individuals with deficient p53 path-
way activity and support this by testing blood 
samples from cancer-prone individuals with 
inherited alterations in the ATM or TP53 genes. 
As anticipated, samples from AT patients and 
AT carriers (who harbor ATM mutations) as well 
as from patients with the Li-Fraumeni cancer 
syndrome (carrying TP53 mutations) showed 
an attenuated expression of PUMA in response 
to ex vivo irradiation. 
Amongst the hundreds of genes up-
regulated by p53, the BBC3 (BCL2-homology 
domain-3 BH3 only) gene, more commonly 
referred to as PUMA, is a pro-apoptotic gene 
that appears to be of central importance in 
executing p53’s role as a tumor suppressor. 
There is a tight correlation between frequency 
in human tumors of a given p53 mutant and 
loss of the mutant’s ability to induce PUMA.5 
The ability of cells to program their own extinc-
tion under conditions that threaten genetic 
integrity depends on Puma6 and its molecular 
collaborators. if the p53 pathway function 
can be conveniently gauged by iR induction 
of PUMA, it will be interesting to see whether 
this simplified screening approach will help 
to reveal p53 pathway deficiencies conferred 
by certain somatic tumor mutations, naturally 
occurring intronic polymorphic mutations,7 or 
germline snPs previously thought to be phe-
notypically silent (Fig. 1). 
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an  altered therapeutic response to tamoxi-
fen. interestingly, in this cohort RB status 
was not associated with prognosis in either 
eR-positive or eR-negative cancers, thus sug-
gesting that the role of RB could be relevant 
for outcomes associated with therapy yet 
holds less significance in predicting overall 
disease course.   
This study represents an important exten-
sion of prior work in this area by showing that 
direct effects on RB status impact the efficacy 
of tamoxifen therapy. This concept is sup-
portive of preclinical studies and the analyses 
of gene expression signatures indicative of 
RB deficiency.11-14 Furthermore, recent work 
in mouse models showed that RB loss can 
contribute to the development of eR-positive 
breast cancers that harbor molecular char-
acteristics of the luminal B subtype.15 such 
models could be particularly relevant for 
determining how alterations in RB-pathway 
function contribute to eR-positive breast can-
cer and tamoxifen resistance. 
now that specific dysfunction in the 
RB-pathway has been identified in select 
patient populations, the key question remains: 
what is the underpinning mechanism that 
leads to RB pathway disruption in eR-positive 
tumors? work from Perou and colleagues sug-
gests that LOH in the Rb1 gene is of likely 
consequence in luminal B breast cancers that 
exhibit poor response to endocrine therapy.13 
similarly, recent studies demonstrated that 
genetic loss at 13q14 was associated with 
lack of RB protein and progression to resis-
tance to hormone therapy in prostate cancer.16 
Therefore, whether tumors that harbor path-
way dysregulation, as identified by Lehn and 
colleagues, actually harbor genetic Rb1 inac-
tivation should be determined. such analyses 
in eR-positive breast cancer could close the 
loop and demonstrate a specific pathologi-
cal impact of RB genetic inactivation on the 
response to tamoxifen therapy. 
The important findings of Lehn and col-
leagues related to RB-pathway dysfunction 
and tamoxifen response will yield a renewed 
interest in determining how cell cycle dereg-
ulation modulates therapeutic response in 
eR-positive breast cancer and provide the seed 
for novel approaches of intervention to yield 
more efficacious treatment.  
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Cutaneous T-cell lymphoma (CTCL) is a class 
of non-Hodgkin lymphoma that forms skin 
lesions due to the accumulation of malignant 
T-helper cells in the skin.1 The main drugs that 
currently approved by FDA for CTCL treatment 
target retinoid X receptors (Bexarotene)2 or 
histone deacetylase (vorinostat, Romidepsin).3 
in a previous issue of Cell Cycle, M. nihal et al. 
reported a new potential target, polo-like 
kinase 1 (Plk1), for treating CTCL.4 Plk1 plays 
a key role in regulation of mitotic entry of pro-
liferating cells. An increased expression of Plk1 
was found in many cancer cells,5-7 including 
CTCL cells,8 which was believed to lead to an 
accelerated proliferation of cancer cells. in this 
study, M. nihal et al. systematically analyzed 
the expression and function of Plk1 in regulat-
ing the fate of CTCL. They demonstrated that 
Plk1 was dramatically increased at both the 
mRnA and protein levels in CTCL. The genetic 
knockdown or functional inhibition of Plk1 led 
to an increase of cell cycle regulators cyclin B1 
and cdc25c. The reduction of Plk1 also results 
in an increase of mitotic error accompanied 
with G2/M phase cell cycle arrest and apoptosis 
of CTCL. These results suggest that targeted 
inhibition of Plk1 can potentially be used to 
treat CTCL.
in normal cells, Plk1 expression is tightly 
regulated at transcriptional and translational 
levels during the cell cycle progression.9 
interestingly, M. nihal et al. showed that the 
increase of Plk1 protein was not always propor-
tionally correlated to the increase of its mRnA 
in different CTCL cell lines. Genetic knockdown 
of Plk1 had only minor effects on Plk1 protein 
level, cell proliferation and/or apoptosis of 
certain CTCL cell lines. These results indicate 
that the accumulation of Plk1 in CTCL could 
be a result of coordinative regulation of Plk1 
expression at transcription, translation and/ or 
post-translation levels. All tested CTCL cell 
lines showed an increased apoptotic death in 
a dose-dependent manner in response to a 
potent ATP-competitive inhibitor of Plk fam-
ily members (Plk1 and Plk3). However, the 
sensitivity towards the inhibitor varied from 
cell line to cell line. in addition, side effects for 
using an ATP-competitive inhibitor is often a 
problem due to non-specificity of the drug. 
These findings lead to a conclusion that, while 
the inhibition of Plk1 can be potentially used 
to treat CTCL, how to target it could be a 
question to ask before treatment. An analysis 
of the mechanism for Plk1 accumulation for 
each case of CTCL may provide guidance and 
improve efficacy for treating CTCL using Plk1 
as a target. 
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Cyclin-dependent kinase 4 (Cdk4) is an 
important component of cell cycle activa-
tion, with critical roles in embryogenesis, 
homeostasis and cancer. in cancer and car-
diovascular disease, Cdks, including Cdk4, are 
considered potential therapeutic targets that 
function independent of cell cycle regulation.1,2 
Chow  et  al. demonstrate that Cdk4-/- mice 
have a hypoplastic thymus and an increase in 
immature CD4/CD8 double negative thymo-
cytes.3 Thymocytes from Cdk4-/- mice, but not 
splenocytes, exhibit decreased adhesion to 
the endothelial cell matrix and fibronectin. The 
authors speculate that lack of Cdk4 impairs the 
ability of thymocytes to migrate to fibronectin 
and affects maturation of thymocyte, since 
T-cell development in the thymus requires 
migration from the cortex to the fibronectin-
rich thymic medulla (Fig. 1). They also address 
the role of Cdk4 in a model of pulmonary aller-
gic (ovalbumin) inflammation. in a previous 
study, analysis of a bleomycin-induced acute 
lung injury model indicates that Cdk4-/- mice 
exhibit impaired recruitment of lymphocytes 
to the lung.4 in contrast, in this study, analysis 
of an allergic model suggests that Cdk4 is not 
critical for lymphocyte recruitment to the lung. 
The authors suggest that the different find-
ings may be due to the different cell types in 
recruitment mediated by Cdk4. For example, 
the cellular response in acute lung injury may 
be due to hematopoietic cells, and, in an aller-
gic model, it may be due to structural cells. 
Differences in rate of exposure and timing are 
also important considerations. These data sup-
port the concept that Cdk4 may play impor-
tant roles in thymocyte maturation and in 
innate (acute lung injury), but not necessarily 
adaptive (allergen), models of inflammation. 
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Figure 1. Maturing thymocytes. The thymus is broadly divided into two histologically defined regions, the cortex and the medulla. T cell precursors 
enter the thymus at the cortico-medullary junction to begin a differentiation program. The cortex contains immature CD4/CD8 double negative (Dn) T 
cells and CD4/CD8 double positive (DP) T cells. The T cells must migrate through the cortex into the medulla to differentiate into mature either CD4 or 
CD8 single positive (sP) T cells. Positive selection occurs in the cortex whereas negative selection occurs in the medulla. sP cells that have completed 
the differentiation program emigrate from the medulla to the periphery. Thymocytes from Cdk4-/- mice exhibit inability to migrate from the cortex to 
the fibronectin-rich medulla and thus to differentiate into mature T cells.
